Commitment to Drug Research and Innovation

Commitment to Drug Research and Innovation swissnex San Francisco - Swissnex Dr. Alice Huxley of Speedel speaks about the need for commitment to research and innovation.Dr. Alice Huxley, CEO of Speedel discusses what it takes to launch a successful company. Some companies launch in a garage, while others are launched in an attic. And that was just the beginning! Today Speedel is a Swiss biopharmaceutical company that recently received the Wall Street Journal's Gold Award for Technology Innovation for their work on Aliskiren, the first renin inhibitor for treating hypertension. Dr. Huxley, who will also be presenting at the J.P. Morgan Healthcare Conference during her visit to the Bay Area, will speak about the need for commitment to research and innovation and the importance of developing new drugs rather than "me-too" products - swissnex

ForaTV | January 12, 2008

Tags:. .renin. .biopharmaceutical. .presenting. .hypertension. .huxley